Showing 3691-3700 of 6035 results for "".
- MetLife to Acquire Versant Health, Owner of Davis Vision and Superior Visionhttps://modernod.com/news/metlife-to-acquire-versant-health-owner-of-davis-vision-and-superior-vision/2478292/MetLife announced it has entered into a definitive agreement to acquire Versant Health from an investor group led by Centerbridge Partners and including FFL Partners for approximately $1.675 billion in an all-cash transaction. Versant Health owns the marketplace brands Davis Vision and Superior V
- 5 Reasons Why Medical Meetings Will Never Be the Samehttps://modernod.com/news/5-reasons-why-medical-meetings-will-never-be-the-same/2478276/In the wake of the COVID-19 pandemic, the virtual medical meeting is now the norm. And while it’s admirable that key data are being disseminated (often for free), there is no escaping the fact that it is a fundamentally different and lesser experience, according to commentary
- Zeiss Launches New Frame and Lens Disinfecting Technology to Support Safety and Hygiene in Eye Care Practiceshttps://modernod.com/news/zeiss-launches-new-frame-and-lens-disinfecting-technology-to-support-safety-hygiene-and-productivity-in-eyecare-practices/2478262/Zeiss Vision Care US announced the launch of the
- Orbis International Announces New CEO & Presidenthttps://modernod.com/news/orbis-international-announces-new-ceo-president/2478251/Orbis International announced the appointment of Derek Hodkey as the organization’s new CEO and President, with immediate effect, following the retirement of Bob Ranck, who led Orbis for over 4 years.
- COVID-19 Vaccine Developers Seek to Reassure Public Over Safetyhttps://modernod.com/news/covid-19-vaccine-developers-seek-to-reassure-public-over-safety/2478249/Sources suggested that a number of drugmakers, including GlaxoSmithKline, Johnson & Johnson and Pfizer, are planning to release a statement outlining their commitment to only seek FDA approval of a vaccine against COVID-19 if it is supported by extensive safety and efficacy data. The move is
- Saliva COVID-19 Test as Good as, Perhaps Beats, Nasal Swab: Studyhttps://modernod.com/news/saliva-covid-19-test-as-good-as-perhaps-beats-nasal-swab-study/2478248/A COVID-19 saliva test protocol developed by researchers at Yale University appeared to perform at least as well as nasal swabs in a study of hospital patients, a finding that may help encourage more frequent use of self-collected samples, according to a Medscape
- Analysis Finds Corticosteroids Cut Risk of Death in Critically Ill COVID-19 Patientshttps://modernod.com/news/analysis-finds-corticosteroids-cut-risk-of-death-in-critically-ill-covid-19-patients/2478240/Results of a meta-analysis published Wednesday in JAMA suggest that the use of systemic corticosteroids in critically ill patients with COVID-19 is associated with lower 28-day all-cause mortality compared to usual care or placebo. Study author Jonathan Sterne noted that the benefit was
- Medical Optometry America to Open First Practice Location in Southcentral Pennsylvaniahttps://modernod.com/news/medical-optometry-america-to-open-first-practice-location-in-southcentral-pennsylvania/2478237/Medical Optometry America (MOA) announced their first practice location will open in Shrewsbury, Pennsylvania in late 2020 and will be led by MOA’s Regional Clinical Director Leslie O’Dell, OD, FAAO. As the first national optometric brand focused exclusively on medical eye care, MOA is lau
- CooperVision Announces Direct-to-Consumer Campaign Featuring Sarah Michelle Gellarhttps://modernod.com/news/coopervision-announces-direct-to-consumer-campaign-featuring-sarah-michelle-gellar/2478209/CooperVision announced popular US television actress, producer, and entrepreneur Sarah Michelle Gellar as the spokesperson for its Brilliant Futures Myopia Management Program. Brilliant Futures is built around MiSight 1 day, the first and only soft contact lens FDA-approved to slow the progressio
- AGTC Announces Publication of Preclinical Data that Support the Ongoing Clinical Development of Its XLRP Gene Therapy Programhttps://modernod.com/news/agtc-announces-publication-of-preclinical-data-that-support-the-ongoing-clinical-development-of-its-xlrp-gene-therapy-program/2478200/Applied Genetic Technologies Corporation (AGTC) announced that preclinical data validating the transgene (hRPGRco) that is being evaluated in the company’s ongoing phase 1/2 clinical trial in patients with X-lined retinitis pigmentosa (XLRP) have been published in the July 15, 2020 print issue of